Achieve Life Sciences Q3 2026 Earnings Date & Estimates

Achieve Life Sciences (NASDAQ:ACHV) is a biopharmaceutical company focused on developing and commercializing cytisinicline, a plant-based investigational therapy intended to help adults quit smoking and address nicotine addiction. Cytisinicline is designed to act on nicotinic acetylcholine receptors in the brain, potentially reducing nicotine cravings and withdrawal symptoms while helping limit the satisfaction associated with smoking.

The company’s primary development program is aimed at securing regulatory approval for cytisinicline in the United States. Achieve has evaluated the therapy in clinical studies involving adults who smoke cigarettes and has also investigated its potential use in helping people quit vaping or using other nicotine products. Cytisinicline has a history of use in certain countries outside the United States under different brand names, although Achieve is conducting its own clinical and regulatory development program for the U.S. market.

Achieve Life Sciences is headquartered in Seattle, Washington, and its operations are centered on clinical development, regulatory activities and commercialization planning for cytisinicline. The company’s leadership includes Chief Executive Officer Rick Stewart, who has experience in the development and commercialization of pharmaceutical products.